Inhibikase Therapeutics, Inc.

Direct answer

Inhibikase Therapeutics, Inc. is publicly traded on NASDAQ under the ticker IKT.

Inhibikase Therapeutics, Inc. operates as a pharmaceutical firm in the clinical development stage, concentrating its efforts on pioneering treatments for Parkinson's Disease (PD) and a range of associated neurological conditions that impact both the brain and other parts of the body. The company's investigational pipeline includes IkT-148009, a small molecule designed to inhibit Abelson tyrosine kinase. This...

Can you invest in Inhibikase Therapeutics, Inc.?

Yes. Inhibikase Therapeutics, Inc. trades publicly on NASDAQ as IKT.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Inhibikase Therapeutics, Inc.

Detailed equity research is provided by MarketSnap.